However, the degraders also inhibit BCR-ABL tyrosine kinase activity, which complicates the value and suitability of BCR-ABL degradation in CML cell growth inhibition by degraders. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.